PT-141, also known by its generic name bremelanotide, is an FDA-approved peptide medication specifically designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. This synthetic melanocortin receptor agonist works through the central nervous system rather than affecting blood flow like traditional erectile dysfunction medications. PT-141 was approved by the FDA in June 2019 under the brand name Vyleesi and is administered as a subcutaneous injection containing 1.75 mg of bremelanotide. Clinical trials demonstrated that 25% of women experienced meaningful improvements in sexual desire compared to 17% taking placebo. The peptide activates melanocortin-4 receptors in the hypothalamus, triggering neurochemical pathways associated with sexual arousal and desire. As of 2026, PT-141 costs approximately $800-1,200 per month for prescribed treatment, though compounded versions may be available through specialized peptide therapy clinics at reduced costs.
Key Takeaways
- PT-141 (bremelanotide) is FDA-approved for treating hypoactive sexual desire disorder in premenopausal women
- Works through melanocortin-4 receptors in the brain, not through vascular mechanisms
- Administered as 1.75 mg subcutaneous injection approximately 45 minutes before anticipated sexual activity
- Clinical efficacy shown in 25% of women versus 17% placebo response rate
- Common side effects include nausea (40% of users), flushing, and injection site reactions
How PT-141 Works in the Body
PT-141 functions as a selective melanocortin-4 receptor agonist, targeting specific neural pathways in the hypothalamus responsible for sexual desire and arousal. Unlike phosphodiesterase-5 inhibitors such as sildenafil that work by increasing blood flow to genital tissues, bremelanotide acts centrally through the nervous system. The peptide crosses the blood-brain barrier and binds to melanocortin-4 receptors, stimulating the release of dopamine and other neurotransmitters associated with sexual motivation.
This mechanism of action makes PT-141 unique among sexual dysfunction treatments. Research published in the Journal of Sexual Medicine showed that the peptide's effects begin within 45 minutes of injection and can last up to 12 hours. The medication's central nervous system approach addresses the psychological and neurochemical components of sexual desire, rather than solely focusing on physical arousal mechanisms.
FDA Approval and Clinical Evidence
The FDA approved PT-141 in June 2019 following two Phase 3 clinical trials involving over 1,200 premenopausal women diagnosed with hypoactive sexual desire disorder. The RECONNECT studies demonstrated statistically significant improvements in sexual desire scores compared to placebo. Women receiving PT-141 showed an average increase of 0.3 points on the Female Sexual Function Index desire domain, while placebo groups showed minimal improvement.
View data table
| Category | Relative Hormone Production (%) | Detail |
|---|---|---|
| 30-39 | 92 | Optimal hormone production |
| 40-49 | 78 | Gradual decline begins |
| 50-59 | 65 | Noticeable changes |
| 60-69 | 52 | Significant decline |
| 70+ | 38 | Marked reduction |
Safety data from these trials revealed that nausea occurred in approximately 40% of participants, making it the most common side effect. Other frequently reported adverse effects included flushing (20% of users), injection site reactions (15%), and headaches (11%). The trials excluded women taking certain antidepressants and those with uncontrolled hypertension due to potential drug interactions and cardiovascular considerations.
Dosing and Administration Guidelines
PT-141 is administered as a 1.75 mg subcutaneous injection using a prefilled autoinjector pen. Patients inject the medication into the abdomen or thigh approximately 45 minutes before anticipated sexual activity. The FDA recommends limiting use to no more than 8 doses per month to minimize the risk of sustained blood pressure elevation and other potential side effects.
Optimize your health with expert guidance
Get a personalized treatment plan after licensed provider review. Free consultation included.
Start Free Assessment →Healthcare providers typically start patients on the standard 1.75 mg dose without titration, as clinical studies did not demonstrate additional benefit from dose escalation. The medication should be stored in the refrigerator between 36°F and 46°F and brought to room temperature before injection. Patients should rotate injection sites to prevent tissue irritation and maintain proper injection technique as demonstrated by their healthcare provider.
Cost and Availability in 2026
As of 2026, brand-name Vyleesi costs approximately $800-1,200 per month for the prescribed 8-dose maximum monthly supply. Most insurance plans classify PT-141 as a specialty medication, requiring prior authorization and often resulting in higher copays ranging from $50-200 per dose. Some patients pursue compounded bremelanotide through specialized clinics offering peptide therapy services, which may reduce monthly costs to $300-600.
The medication remains available only by prescription from licensed healthcare providers. Telemedicine platforms specializing in sexual health have expanded access to PT-141 consultations, though patients must still obtain the medication through legitimate pharmacies. Compounding pharmacies that also prepare medications like BPC-157 and Ipamorelin may offer alternative formulations, though quality and consistency can vary compared to FDA-approved products.
Frequently Asked Questions
Is PT-141 safe for men to use?
PT-141 is FDA-approved only for premenopausal women with hypoactive sexual desire disorder. While some men use compounded bremelanotide off-label, clinical safety and efficacy data in males is limited. Men considering PT-141 should consult with healthcare providers familiar with peptide therapies to discuss potential risks, benefits, and alternative treatments for sexual dysfunction.
How does PT-141 differ from Viagra or Cialis?
PT-141 works through the central nervous system by targeting brain receptors that control sexual desire, while Viagra and Cialis work by increasing blood flow to genital tissues. PT-141 addresses psychological and neurochemical aspects of sexual dysfunction, whereas PDE-5 inhibitors primarily treat physical erectile dysfunction. The mechanisms and target patient populations are distinctly different.
Can PT-141 be taken with other medications?
PT-141 can interact with certain medications, particularly those affecting blood pressure and serotonin levels. Patients taking MAO inhibitors, certain antidepressants, or blood pressure medications should discuss potential interactions with their healthcare provider. Always provide a complete medication list to your doctor before starting PT-141 therapy.
What should I expect during my first PT-141 injection?
Most patients experience mild injection site discomfort similar to other subcutaneous injections. Nausea occurs in about 40% of users, typically beginning 15-30 minutes after injection and lasting 2-4 hours. Starting with the injection on an empty stomach may reduce nausea severity. Have anti-nausea medication available if recommended by your healthcare provider.
Sources
- Clayton AH, et al. Safety and efficacy of bremelanotide for hypoactive sexual desire disorder: A randomized placebo-controlled trial. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599830
- Simon JA, et al. Efficacy and safety of bremelanotide for the treatment of hypoactive sexual desire disorder in women: RECONNECT Study. J Sex Med. 2019;16(11):1701-1709. PMID: 31540713
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599831
- FDA Drug Approval Package: Vyleesi (bremelanotide) injection. Center for Drug Evaluation and Research. 2019.
- Pfaus JG, et al. Bremelanotide: Neural pathways and mechanism of action. Pharmacol Biochem Behav. 2020;189:172835. PMID: 31891756
- Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. PMID: 16839319
- Rosen RC, et al. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191-208. PMID: 10782451